Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis, cell adhesion, and lymphocyte migration and homing. Through these multiple actions, BTK helps to direct malignant B cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.
The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program includes 23 clinical trials – six Phase 3, nine Phase 2, one Phase 1/2, and seven Phase 1 trials currently underway.
About the Janssen and Pharmacyclics Collaboration
Janssen Biotech, Inc. and Pharmacyclics Inc. entered into a worldwide collaboration on December 8, 2011, to develop and commercialize ibrutinib. Following regulatory approval, Janssen and Pharmacyclics will co-commercialize ibrutinib. In the United States, both companies will share in commercialization activities; outside the United States, Janssen will lead and perform commercialization activities. Each company is leading development for specific indications.
About Janssen Research & Development, LLC
Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel
|SOURCE Janssen Research & Development, LLC|
Copyright©2012 PR Newswire.
All rights reserved